Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $165.75 | Total: $828.75 |
| 1 | 10 | $140.40 | Total: $1,404.00 |
| 1 | 25 | $118.95 | Total: $2,973.75 |
| 1 | 50 | $101.40 | Total: $5,070.00 |
| 1 | 100 | $87.75 | Total: $8,775.00 |
Overview
RP-6306 is a potent, selective and orally active PKMYT1 inhibitor (IC50= 14 nM). RP-6306 exhibits a high degree of selectivity for PKMYT1 over other kinases in cellular binding assays. RP-6306 exhibits anticancer effects.
Chemical Properties
| Molecular Formula | C18H20N4O2 |
| Molecular Weight | 324.38 |
| CAS Numbers | 2719793-90-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | NC=1N(C=2C(C1C(N)=O)=CC(C)=C(C)N2)C3=C(C)C(O)=CC=C3C |
Storage and Handling
0C Short Term, -20C Long Term
References
Janek Szychowski, et al. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306. J Med Chem. 2022 Aug 11;65[15] 10251-10284.